DNLI - Denali Therapeutics Inc Stock Price, Fair Value and News

14.96USD-0.60 (-3.86%)Market Closed

Market Summary

USD14.96-0.60

Market Closed

-3.86%

DNLI Alerts

1 major insider sales recently.

DNLI Stock Price

View Fullscreen

DNLI RSI Chart

DNLI Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-14.34

Price/Sales (Trailing)

6.3

Price/Free Cashflow

-5.61

DNLI Price/Sales (Trailing)

DNLI Profitability

Return on Equity

-14.09%

Return on Assets

-12.59%

Free Cashflow Yield

-17.82%

DNLI Fundamentals

DNLI Revenue

Revenue (TTM)

330.5M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

DNLI Earnings

Earnings (TTM)

-145.2M

Earnings Growth (Yr)

-21.07%

Earnings Growth (Qtr)

-20.25%

Breaking Down DNLI Revenue

Last 7 days

-9.8%

Last 30 days

-24.6%

Last 90 days

-11.2%

Trailing 12 Months

-38.5%

How does DNLI drawdown profile look like?

DNLI Financial Health

Current Ratio

13.65

DNLI Investor Care

Shares Dilution (1Y)

1.82%

Diluted EPS (TTM)

-1.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	101.5M	343.1M	340.8M	330.5M
2022	82.9M	112.4M	110.7M	108.5M
2021	263.9M	192.2M	120.4M	48.7M
2020	26.1M	27.7M	23.5M	335.7M
2019	103.5M	77.9M	52.3M	26.7M
2018	0	0	0	129.2M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Denali Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	sato vicki l	sold	-30,471	18.29	-1,666	-
Apr 01, 2024	krognes steve e.	sold	-1,896,250	20.5	-92,500	-
Mar 29, 2024	watts ryan j.	gifted	-	-	-40,000	president and ceo
Mar 15, 2024	sato vicki l	sold	-33,486	20.1	-1,666	-
Feb 15, 2024	sato vicki l	sold	-30,604	18.37	-1,666	-
Feb 14, 2024	ho carole	sold	-24,994	17.79	-1,405	chief medical officer
Feb 14, 2024	schuth alexander o.	sold	-355,460	17.66	-20,128	cofo and secretary
Feb 13, 2024	watts ryan j.	sold	-165,794	17.29	-9,589	president and ceo
Feb 13, 2024	ho carole	sold	-48,135	17.29	-2,784	chief medical officer
Feb 13, 2024	schuth alexander o.	sold	-46,959	17.29	-2,716	cofo and secretary

Which funds bought or sold DNLI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Activest Wealth Management	unchanged	-	-123	2,688	-%
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	-101,000	1,323,000	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.41	-283,000	83,000	-%
Apr 23, 2024	Morton Brown Family Wealth, LLC	sold off	-100	-6,395	-	-%
Apr 23, 2024	Global Retirement Partners, LLC	added	266	171	226	-%
Apr 22, 2024	ARTHUR M. COHEN & ASSOCIATES, LLC	sold off	-100	-226,703	-	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	51,679	1,336,180	0.01%
Apr 19, 2024	Cutler Group LLC / CA	unchanged	-	-	8,000	-%
Apr 18, 2024	WASATCH ADVISORS LP	added	28.94	1,560,810	8,262,790	0.04%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	9.2	5,348	126,403	-%

Are Funds Buying or Selling DNLI?

Are funds buying DNLI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DNLI

No. of Funds

DNLI Alerts

1 major insider sales recently.

Unveiling Denali Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	bratton douglas k	4.2%	5,750,882	SC 13G/A
Feb 13, 2024	vanguard group inc	7.84%	10,834,483	SC 13G/A
Feb 12, 2024	biogen inc.	75%	12,751,365	SC 13G/A
Feb 08, 2024	wellington management group llp	5.26%	7,274,717	SC 13G
Jan 30, 2024	baillie gifford & co	10.32%	14,260,724	SC 13G/A
Jan 30, 2024	temasek holdings (private) ltd	4.9%	6,895,992	SC 13G/A
Jan 25, 2024	blackrock inc.	8.4%	11,542,861	SC 13G/A
Mar 30, 2023	temasek holdings (private) ltd	5.0%	6,895,992	SC 13G
Feb 13, 2023	bratton douglas k	5.2%	7,000,882	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of Denali Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	ARS	ARS
Apr 18, 2024	DEF 14A	DEF 14A
Apr 18, 2024	DEFA14A	DEFA14A
Apr 17, 2024	4	Insider Trading
Apr 15, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 29, 2024	4	Insider Trading
Mar 22, 2024	S-3ASR	S-3ASR
Mar 19, 2024	4	Insider Trading

Peers (Alternatives to Denali Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.13	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Denali Therapeutics Inc News

Latest updates

Denali Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-100.0%	-	1.00	294	35.00	10.00	4.00	52.00	42.00	13.00	5.00	23.00	170	317	9.00	6.00	4.00	5.00	14.00	4.00	65.00	126
Operating Expenses	15.2%	133	115	124	156	116	111	114	109	90.00	91.00	85.00	79.00	73.00	70.00	67.00	64.00	62.00	64.00	67.00	47.00	51.00
S&GA Expenses	-2.2%	25.00	25.00	26.00	27.00	24.00	23.00	21.00	23.00	22.00	19.00	19.00	19.00	18.00	16.00	14.00	13.00	11.00	11.00	15.00	9.00	11.00
R&D Expenses	20.1%	108	90.00	98.00	129	92.00	88.00	93.00	86.00	68.00	72.00	66.00	60.00	55.00	54.00	53.00	51.00	52.00	53.00	52.00	37.00	40.00
Income Taxes	-	0.00	-	-	0.00	-0.01	-	0.00	-	-0.57	-	-	-	1.00	0.00	0.00	-0.10	0.00	-0.10	-0.30	-	-
Net Income	-20.3%	-119	-99.35	183	-109	-98.68	-103	-58.79	-65.22	-75.26	-84.59	-60.69	-70.04	245	-58.23	-58.76	-56.76	-54.02	-46.26	-58.34	-38.99	78.00
Net Income Margin	-20.3%	-0.44*	-0.37*	-0.37*	-3.65*	-3.01*	-2.73*	-2.53*	-3.45*	-5.97*	0.25*	0.29*	0.22*	-	-	-	-	-	-	-	-	-
Free Cashflow	-12.8%	-100	-89.43	-119	-61.59	-77.51	-63.10	-45.79	-76.15	-68.55	-43.31	-54.99	-53.04	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-6.7%	1,154	1,237	1,306	1,409	1,460	1,228	1,292	1,321	1,404	1,450	1,510	1,548	1,604	1,070	647	696	553	603	638	677	662
Current Assets	-6.9%	1,064	1,143	1,224	1,325	1,372	1,139	1,115	988	897	1,056	1,342	1,432	1,496	971	559	605	430	494	496	500	481
Cash Equivalents	-14.1%	127	148	132	68.00	218	120	157	106	295	396	487	437	509	353	139	209	81.00	83.00	63.00	40.00	79.00
Net PPE	-5.2%	46.00	48.00	40.00	42.00	44.00	42.00	39.00	38.00	39.00	40.00	40.00	41.00	41.00	42.00	44.00	45.00	47.00	47.00	47.00	37.00	25.00
Liabilities	3.8%	123	118	119	443	418	416	408	403	442	438	437	443	454	188	145	151	158	165	162	160	115
Current Liabilities	9.6%	78.00	71.00	69.00	391	364	361	348	341	378	54.00	51.00	55.00	72.00	105	58.00	48.00	45.00	47.00	47.00	43.00	33.00
Shareholder's Equity	-7.8%	1,031	1,118	1,187	967	1,042	811	884	918	962	1,012	1,073	1,105	1,151	883	502	545	395	438	475	517	547
Retained Earnings	-12.0%	-1,116	-996	-897	-1,080	-970	-872	-769	-710	-645	-569	-485	-424	-354	-599	-541	-482	-425	-371	-325	-266	-227
Additional Paid-In Capital	1.5%	2,145	2,114	2,084	2,048	2,019	1,694	1,664	1,636	1,608	1,581	1,557	1,529	1,504	1,480	1,041	1,025	819	808	798	782	774
Shares Outstanding	0.2%	138	138	137	137	136	123	123	123	122	122	121	121	-	-	-	-	-	-	-	-	-
Float	-	-	-	2,000	-	-	-	1,500	-	-	-	2,800	-	-	-	851	-	-	-	716	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-12.9%	-98.66	-87.36	-113	-58.80	-72.66	-57.05	-42.90	-72.11	-65.49	-41.43	-54.22	-50.24	514	0.00	-43.36	-54.49	-47.64	-30.43	-43.17	-30.32	93.00
Share Based Compensation	-5.4%	26.00	27.00	27.00	28.00	25.00	25.00	24.00	26.00	22.00	21.00	21.00	21.00	14.00	13.00	12.00	11.00	9.00	9.00	14.00	7.00	6.00
Cashflow From Investing	-27.6%	73.00	101	168	-92.71	-127	15.00	89.00	-117	-40.75	-53.01	98.00	-25.40	-367	-212	-30.41	-13.33	42.00	49.00	64.00	-8.05	-61.40
Cashflow From Financing	88.8%	5.00	2.00	9.00	2.00	300	5.00	4.00	1.00	5.00	3.00	7.00	4.00	10.00	426	3.00	196	2.00	1.00	3.00	1.00	2.00

DNLI Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Collaboration revenue:

Collaboration revenue from customers

^[1]

$ 330,531

$ 105,065

$ 48,657

Other collaboration revenue

3,398

Total collaboration revenue

330,531

108,463

48,661

Operating expenses:

Research and development expense

^[2]

423,876

358,732

265,353

General and administrative

103,354

90,475

79,059

Total operating expenses

527,230

449,207

344,412

Loss from operations

(196,699)

(340,744)

(295,751)

Interest and other income, net

51,505

14,774

4,595

Loss before income taxes

(145,194)

(325,970)

(291,156)

Income tax benefit (expense)

(30)

(21)

575

Net loss

(145,224)

(325,991)

(290,581)

Other comprehensive income (loss):

Net unrealized gain (loss) on marketable securities, net of tax

7,529

(4,387)

(2,254)

Comprehensive loss

$ (137,695)

$ (330,378)

$ (292,835)

Net loss per share:

Net loss per share, basic (usd per share)

$ (1.06)

$ (2.60)

$ (2.39)

Net loss per share, diluted (usd per share)

$ (1.06)

$ (2.60)

$ (2.39)

Weighted-average shares used in calculating:

Weighted average number of shares outstanding, basic (in shares)

137,370,897

125,530,703

121,524,795

Weighted average number of shares outstanding, diluted (in shares)

137,370,897

125,530,703

121,524,795

[1]	Includes related-party collaboration revenue from customers of $295.5 million, $3.2 million, and $3.7 million for the years ended December 31, 2023, 2022 and 2021 respectively.
[2]	Includes expense for cost sharing payments to a related party of $17.7 million and $8.2 million for the years ended December 31, 2023 and 2022, respectively, and an offset to expense from related-party cost reimbursements of $6.5 million for the year ended December 31, 2021.

DNLI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 127,106	$ 218,044
Short-term marketable securities	907,405	1,118,171
Prepaid expenses and other current assets	29,626	36,104
Total current assets	1,064,137	1,372,319
Property and equipment, net	45,589	44,087
Operating lease right-of-use asset	26,048	30,437
Other non-current assets	18,143	13,399
Total assets	1,153,917	1,460,242
Current liabilities:
Accounts payable	9,483	2,790
Cost sharing payments due to related party	0	4,388
Accrued expenses and other current liabilities	68,499	66,691
Contract liabilities, current	0	290,053
Total current liabilities	77,982	363,922
Contract liabilities, less current portion	0	479
Operating lease liability, less current portion	44,981	53,032
Other non-current liabilities	0	379
Total liabilities	122,963	417,812
Commitments and contingencies (Note 8)
Stockholders’ equity:
Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022	0	0
Common stock, $0.01 par value; 400,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 138,385,498 and 135,965,918 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	1,711	1,686
Additional paid-in capital	2,144,811	2,018,617
Accumulated other comprehensive income (loss)	643	(6,886)
Accumulated deficit	(1,116,211)	(970,987)
Total stockholders’ equity	1,030,954	1,042,430
Total liabilities and stockholders’ equity	$ 1,153,917	$ 1,460,242

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease; TAK-594/DNL593, which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919, which is in Phase I clinical trials for the treatment of Alzheimer's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788, which is in phase II clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, Genzyme Corporation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

CEO	Dr. Ryan J. Watts Ph.D.
WEBSITE	denalitherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	438

Denali Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Denali Therapeutics Inc? What does DNLI stand for in stocks?

DNLI is the stock ticker symbol of Denali Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Denali Therapeutics Inc (DNLI)?

As of Thu Apr 25 2024, market cap of Denali Therapeutics Inc is 2.08 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DNLI stock?

You can check DNLI's fair value in chart for subscribers.

What is the fair value of DNLI stock?

You can check DNLI's fair value in chart for subscribers. The fair value of Denali Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Denali Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DNLI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Denali Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether DNLI is over valued or under valued. Whether Denali Therapeutics Inc is cheap or expensive depends on the assumptions which impact Denali Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DNLI.

What is Denali Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, DNLI's PE ratio (Price to Earnings) is -14.35 and Price to Sales (PS) ratio is 6.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DNLI PE ratio will change depending on the future growth rate expectations of investors.